CLINICAL_TRIALS
trial_result
· 2013-08-26
Clinical Trial Update: The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life [Phase 4]
Summary
Phase 4 study evaluating galantamine (Reminyl ER) in patients with mixed dementia, assessing its effects on cognition and quality of life.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Janssen-Cilag Farmaceutica Ltda. | Conditions: Dementia | Phase 4 | Status: COMPLETED | Results posted: 2013-08-26